Genetically engineered insulin and its pharmaceutical analogues

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry

• Publication date

  2008-11-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1134/S1990750808040057
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Methods for protecting silica sorbents used in high-performance liquid chromatography from strongly adsorbed impurities during purification of human recombinant insulin.

  2007cited by this paper
• The role for insulin analogues in diabetes care

  2006cited by this paper
• Ligand binding and thermostability of different allosteric states of the insulin zinc-hexamer.

  2006cited by this paper
• Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?

  2006cited by this paper
• Molecular variants and derivatives of insulin for improved glycemic control in diabetes.

  2006cited by this paper
• Insulin therapy: current alternatives.

  2005cited by this paper
• Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

  2005cited by this paper
• Über Inhalation von Insulin

  2005cited by this paper
• Transmucosal macromolecular drug delivery.

  2005cited by this paper
• Solution structure of human proinsulin C‐peptide

  2005cited by this paper
• Determination of protamine peptides in insulin drug products using reversed phase high performance liquid chromatography.

  2005cited by this paper
• Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.

  2004cited by this paper
• Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects.

  2004cited by this paper
• Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes.

  2004cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.

  2004cited by this paper
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

  2004cited by this paper
• Prospective audit of conversion from regular to lispro insulin during routine clinical care

  2004cited by this paper
• The effects of smoking and its cessation on 8‐epi‐PGF2α and transforming growth factor‐beta 1 in Type 1 diabetes mellitus

  2004cited by this paper
• Initiation of insulin glargine in children and adolescents with type 1 diabetes

  2004cited by this paper
• Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

  2004cited by this paper
• Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.

  2004cited by this paper
• Preprandial vs. postprandial insulin lispro—a comparative crossover trial in patients with Type 1 diabetes

  2004cited by this paper
• Insulin therapy in type 2 diabetes: role of the long‐acting insulin glargine analogue

  2004cited by this paper
• Maintaining glycaemic control during high‐dose prednisolone administration for hyperemesis gravidarum in Type 1 diabetes

  2004cited by this paper
• A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes

  2003cited by this paper
• Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.

  2003cited by this paper
• Comparative effect of human soluble insulin and insulin aspart upon hypoglycaemia-induced alterations in cardiac repolarization.

  2003cited by this paper
• Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus.

  2003cited by this paper
• Effect of the rapid‐acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes

  2003cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure

  2003cited by this paper
• A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.

  2003cited by this paper
• [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action.

  2003cited by this paper
• Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

  2003cited by this paper
• Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart and Human Insulin

  2003cited by this paper
• Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation.

  2002cited by this paper
• Engineering-enhanced Protein Secretory Expression in Yeast with Application to Insulin* 210

  2002cited by this paper
• A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.

  2002cited by this paper
• Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

  2002cited by this paper
• Basal‐bolus insulin therapy in Type 1 diabetes: comparative study of pre‐meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

  2002cited by this paper
• New insulins in the treatment of diabetes mellitus.

  2002cited by this paper
• Design of biodegradable particles for protein delivery.

  2002cited by this paper
• New horizons — alternative routes for insulin therapy

  2002cited by this paper
• Inhaled Insulin and Insulin Antibodies: A New Twist to an Old Debate

  2002cited by this paper
• The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ System

  2002cited by this paper
• Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2

  2002cited by this paper
• Insulins today and beyond.

  2001cited by this paper
• Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection.

  2001cited by this paper
• Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes

  2001cited by this paper
• Global and societal implications of the diabetes epidemic

  2001cited by this paper
• Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

  2001cited by this paper
• Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance.

  2001cited by this paper
• Human insulin analog insulin aspart does not cause insulin allergy.

  2001cited by this paper
• Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus

  2001cited by this paper
• The insulin analog aspart: a safe alternative in insulin allergy.

  2001cited by this paper
• Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes.

  2001cited by this paper
• Safety of insulin glargine.

  2000cited by this paper
• Design and In Vivo Evaluation of An Oral Delivery System for Insulin

  2000cited by this paper
• Yeast secretory expression of insulin precursors

  2000cited by this paper
• Lipoinsulin encapsulated alginate-chitosan capsules: intestinal delivery in diabetic rats

  2000cited by this paper
• A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

  2000cited by this paper
• Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

  2000cited by this paper
• Insulin analogues and their potential in the management of diabetes mellitus

  1999cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.

  1999cited by this paper
• Applications of yeast in biotechnology: protein production and genetic analysis.

  1999cited by this paper
• Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

  1998cited by this paper
• Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.

  1998cited by this paper
• Proinsulin: recent observations and controversies

  1998cited by this paper
• Expression, purification and characterization of recombinant human proinsulin

  1997cited by this paper
• The new era of biotech insulin analogues

  1997cited by this paper
• Time‐action Profile of the Insulin Analogue B28Asp

  1996cited by this paper
• Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin

  1996cited by this paper
• Computer-aided process analysis and economic evaluation for biosynthetic human insulin production-A case study.

  1995cited by this paper
• Ultrasound-mediated transdermal protein delivery

  1995cited by this paper
• Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin.

  1995cited by this paper
• Crystallographic evidence for dual coordination around zinc in the T3R3 human insulin hexamer.

  1994cited by this paper
• [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

  1994cited by this paper
• Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes.

  1993cited by this paper
• The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.

  1993cited by this paper
• Recombinant Human Insulin

  1992cited by this paper
• The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake.

  1992cited by this paper
• Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy Subjects

  1991cited by this paper
• Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography.

  1990cited by this paper
• Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer

  1989cited by this paper
• Production scale purification of biosynthetic human insulin by reversed-phase high-performance liquid chromatography.

  1989cited by this paper
• The Action Profiles of Human NPH Insulin Preparations

  1989cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper
• A superactive insulin: [B10-aspartic acid]insulin(human).

  1987cited by this paper
• Galenics of Insulin

  1987cited by this paper
• Biochemical and clinical implications of proinsulin conversion intermediates.

  1985cited by this paper
• CHANGES IN RECEPTOR BINDING, BIOLOGICAL ACTIVITY AND IMMUNOREACTIVITY OF INSULIN CAUSED BY REPLACING THE RESIDUES B23-B26 VVITH ALANINE

  1984cited by this paper
• Clinical Factors Influencing the Absorption of 125I-NPH Insulin in Diabetic Patients

  1983cited by this paper
• Identification of a mutant human insulin predicted to contain a serine-for-phenylalanine substitution.

  1983cited by this paper
• Commercial Production of Recombinant DNA-Derived Products

  1983cited by this paper
• Conversion of proinsulin to insulin: involvement of a 31,500 molecular weight thiol protease.

  1982cited by this paper
• Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins.

  1982cited by this paper
• Recombinant DNA — A new source of insulin

  1980cited by this paper
• Role of zinc in insulin biosynthesis

  1980cited by this paper
• Expression in Escherichia coli of chemically synthesized genes for human insulin.

  1979cited by this paper

• No citing papers are available for this paper.